| ASH 2022 ABSTRACTS | |||||
|---|---|---|---|---|---|
| ABSTRACT | WEB LINK | LEAD AUTHOR | SENIOR AUTHOR | MER DATA | LEO DATA |
| 953 FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma | https://doi.org/10.1182/blood-2022-157194 | Maurer | Cerhan | yes | yes |
| 2860 Prediction of Early Disease Progression at 24 Months (POD24) Using Pre-Treatment Biopsies from Patients with Follicular Lymphoma (FL) Treated with Immunochemotherapy (IC) | https://doi.org/10.1182/blood-2022-160351 | Wright | Rimsza | yes | no |
| 724 Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL | https://doi.org/10.1182/blood-2022-159620 | Wenzl | Novak | yes | no |
| 1541 Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma | https://doi.org/10.1182/blood-2022-170228 | Stokes | Gandhi | yes | no |
| 2957 Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortium | https://doi.org/10.1182/blood-2022-157083 | Day | Link | yes | yes |
| 2889 Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma | https://doi.org/10.1182/blood-2022-167633 | Tawfiq | Yucai | CReWE | no |
| 2900 Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting | https://doi.org/10.1182/blood-2022-165419 | Gile | Yucai | CReWE | no |
| 1591 Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study | https://doi.org/10.1182/blood-2022-164988 | Ruan | Feldman | yes | yes |
| 4156 Molecular Landscape of Primary Refractory DLBCL | https://doi.org/10.1182/blood-2022-156497 | Bock | Novak | yes | no |
| 545 A Genome-Wide Association Study (GWAS) of Event-Free Survival (EFS) in Follicular Lymphoma Patients Treated with Front-Line Immunochemotherapy: A Lysa, Iowa/Mayo MER, and FIL Study | https://doi.org/10.1182/blood-2022-167466 | Herve | Cerhan | yes | no |
| 2966 Dose Intensity and Reasons for Dose Alterations in Patients Excluded from Frontline Diffuse Large B-Cell Lymphoma Clinical Trials Based on Eligibility Criteria: A Mayo Clinic Cohort Study | https://doi.org/10.1182/blood-2022-169575 | Khurana | Maurer | yes | no |
| 850 Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis | https://doi.org/10.1182/blood-2022-169433 | Khurana | Nowakowski | no | yes |
| 4207 Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group | https://doi.org/10.1182/blood-2022-162688 | Alduruccio | Lossos | no | yes |
| 798 Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era | https://doi.org/10.1182/blood-2022-165207 | Desai | Cerhan | yes | no |
| 793 Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma | https://doi.org/10.1182/blood-2022-164692 | Luan | Martin | yes | yes |
| 313 Development and Validation of the advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium | https://doi.org/10.1182/blood-2022-164720 | Rodday | Parsons | yes | no |
| Hypomagnesemia in Untreated Diffuse Large B-cell Lymphoma | https://doi.org/10.1182/blood-2022-156361 | Gile | Witzig | yes | no |